Valuation: Cingulate Inc.

Market Cap 72.46M 63.35M 58.22M 54.26M 103M 6.9B 104M 699M 272M 3.39B 272M 266M 11.69B P/E 2026 *
-2.29x
P/E 2027 * -5.36x
Enterprise Value 72.46M 63.35M 58.22M 54.26M 103M 6.9B 104M 699M 272M 3.39B 272M 266M 11.69B EV / Sales 2026 *
25x
EV / Sales 2027 * 3.62x
Free-Float
69.46%
Yield 2026 *
-
Yield 2027 * -
1 day-8.66%
1 week+8.47%
Current month-1.65%
1 month+19.69%
3 months-12.38%
6 months+13.26%
Current year+23.96%
1 week 5.25
Extreme 5.2526
6.04
1 month 4.43
Extreme 4.426
6.04
Current year 3.16
Extreme 3.16
11.89
1 year 3.16
Extreme 3.16
11.89
3 years 1.8
Extreme 1.8001
254.4
5 years 1.8
Extreme 1.8001
1,236
10 years 1.8
Extreme 1.8001
1,236
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 2017-12-31
Chief Tech/Sci/R&D Officer 69 2017-12-31
Chief Executive Officer 51 2012-04-30
Director TitleAgeSince
Director/Board Member 87 2018-05-31
Director/Board Member 59 2018-05-31
Director/Board Member 48 2024-02-12
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Founder

3,885 0.0293%
03-30Free

Founder

3,422 0.0442%
03-08Free

Founder

5,551 0.0717%
Change 5-day change 1-year change 3-year change Capi.($)
-8.66%+8.47%+25.70%-97.53% 72.46M
+1.70%+7.41%+2.50%+8.18% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+0.32%+0.58%+14.00%+19.09% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +1.09%+6.54%+73.47%+94.46% 24.57B
Weighted average by Cap. +2.06%+6.54%+90.18%+135.79%

Financials

2026 *2027 *
Net sales 2.89M 2.53M 2.33M 2.17M 4.11M 276M 4.17M 27.91M 10.85M 135M 10.86M 10.63M 467M 20.04M 17.52M 16.1M 15M 28.46M 1.91B 28.89M 193M 75.12M 938M 75.21M 73.59M 3.23B
Net income -29.32M -25.64M -23.56M -21.96M -41.65M -2.79B -42.28M -283M -110M -1.37B -110M -108M -4.73B -13.31M -11.64M -10.7M -9.97M -18.91M -1.27B -19.2M -128M -49.91M -623M -49.97M -48.9M -2.15B
Net Debt - -
Logo Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Employees
14
Date Price Change Volume
26-07-02 US$5.380 -8.66% 378,203
26-07-01 US$5.890 +7.68% 397,066
26-06-30 US$5.470 +2.82% 345,131
26-06-29 US$5.320 +7.26% 417,023
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.380USD
Average target price
23.00USD
Spread / Average Target
+327.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CING Stock